
đ§ TIA & Stroke Management: Updated Evidence-Based Approach
Mediverse Blog
Catagories:
,
4/12/2025 | 5:17:57 AM
đ§ TIA & Stroke Management: Updated Evidence-Based Approach
Transient IschemIic Attack (TIA) āĻšāϞā§, āĻāĻāύ āĻā§āĻāĻžāĻŦā§ Antiplatelet āϏā§āĻāĻžāϰā§āĻ āĻāϰāĻŦā§āύ?
â Latest guidelines āĻŦāϞāĻā§, high-risk TIA āĻŦāĻž minor stroke āĻšāϞ⧠āĻĻā§āϰā§āϤ dual antiplatelet therapy (DAPT) āĻļā§āϰ⧠āĻāϰāĻž āĻāĻāĻŋāϤāĨ¤
â
Evidence-based āĻāĻŋāĻāĻŋā§āϏāĻž āĻĒā§āϰāϝāĻŧā§āĻ āĻāϰāϞ⧠stroke recurrence ⧍ā§Ģâā§Šā§Ļ% āĻĒāϰā§āϝāύā§āϤ āĻāĻŽāĻžāύ⧠āϏāĻŽā§āĻāĻŦāĨ¤
đ 1. Acute TIA/Stroke Management (Within 12 Hours)
đš First-Line Therapy: Dual Antiplatelet Therapy (DAPT)
High-risk TIA (ABCD² score âĨ 4) āĻŦāĻž Minor Stroke āĻšāϞ⧠āĻĻā§āϰā§āϤ dual antiplatelet therapy (DAPT) āĻļā§āϰ⧠āĻāϰāĻž āĻšāϝāĻŧ, āϝāĻž stroke recurrence āĻāĻŽāĻžāϤ⧠āĻĒā§āϰāĻŽāĻžāĻŖāĻŋāϤāĨ¤
đ Evidence-Based DAPT Regimen:
1ī¸âŖ Clopidogrel 300â600 mg loading dose
2ī¸âŖ Then Clopidogrel 75 mg/day + Aspirin (50â325 mg/day) for 21 days
3ī¸âŖ After 21 days: Switch to Monotherapy (Aspirin 81 mg/day OR Clopidogrel 75 mg/day)
đŦ Clinical Trials Supporting This Approach:
âī¸ CHANCE Trial (2013, China): ⧍⧧ āĻĻāĻŋāύā§āϰ āĻāύā§āϝ Aspirin + Clopidogrel āĻŦā§āϝāĻŦāĻšāĻžāϰ āĻāϰāϞ⧠stroke recurrence 32% āĻāĻŽā§ āϝāĻžāϝāĻŧāĨ¤
âī¸ POINT Trial (2018, USA & Europe): 90 āĻĻāĻŋāύā§āϰ DAPT-āĻāϰ āϤā§āϞāύāĻžāϝāĻŧ ⧍⧧ āĻĻāĻŋāύā§āϰ DAPT āĻŦā§āĻļāĻŋ āύāĻŋāϰāĻžāĻĒāĻĻ (hemorrhage risk āĻāĻŽ)āĨ¤
đĢ Caution:
âĸ ⧍⧧ āĻĻāĻŋāύā§āϰ āĻŦā§āĻļāĻŋ DAPT āĻāĻžāϞāĻŋāϝāĻŧā§ āĻā§āϞ⧠hemorrhagic stroke-āĻāϰ āĻā§āĻāĻāĻŋ āĻŦā§āĻĄāĻŧā§ āϝāĻžāϝāĻŧāĨ¤ āϤāĻžāĻ āύāĻŋāϰā§āĻĻāĻŋāώā§āĻ āϏāĻŽāϝāĻŧ āĻĒāϰ⧠monotherapy āĻāĻžāϞāĻŋāϝāĻŧā§ āϝā§āϤ⧠āĻšāϝāĻŧāĨ¤
âĸ Aspirin āĻ Clopidogrel āĻāĻāϏāĻžāĻĨ⧠⧝ā§Ļ āĻĻāĻŋāύā§āϰ āĻŦā§āĻļāĻŋ āĻŦā§āϝāĻŦāĻšāĻžāϰ āĻāϰāĻž āĻāĻāĻŋāϤ āύāϝāĻŧāĨ¤
đŠē 2. TIA/Stroke with Intracranial Artery Stenosis (70â99%)
đš Extended DAPT for Severe Stenosis
TIA āĻŦāĻž Stroke āϝāĻĻāĻŋ ā§ā§Ļ-⧝⧝% intracranial arterial stenosis-āĻāϰ āĻāĻžāϰāĻŖā§ āĻšāϝāĻŧ, āϤāĻŦā§ standard ⧍⧧ āĻĻāĻŋāύā§āϰ āĻĒāϰāĻŋāĻŦāϰā§āϤ⧠⧝ā§Ļ āĻĻāĻŋāύā§āϰ āĻāύā§āϝ DAPT āĻāĻžāϞāĻŋāϝāĻŧā§ āϝāĻžāĻāϝāĻŧāĻž āĻšāϝāĻŧāĨ¤
â
Recommended DAPT Regimen (90 Days):
âī¸ Aspirin + Clopidogrel for 90 days
âī¸ Then switch to long-term monotherapy (Aspirin or Clopidogrel)
đ Why 90 Days?
âĸ SAMPRISS Trial (2011): Intracranial artery stenosis āĻĨāĻžāĻāϞ⧠stent-āĻāϰ āϤā§āϞāύāĻžāϝāĻŧ DAPT + aggressive risk factor control āĻŦā§āĻļāĻŋ āĻāĻžāϰā§āϝāĻāϰāĨ¤
âĸ RESPECT Trial (2020): ⧝ā§Ļ āĻĻāĻŋāύ āĻĒāϰ DAPT āĻāĻžāϞāĻŋāϝāĻŧā§ āĻā§āϞ⧠hemorrhagic risk āĻŦā§āĻĄāĻŧā§ āϝāĻžāϝāĻŧ, āĻāĻŋāύā§āϤ⧠stroke prevention benefit āĻāĻŽā§ āϝāĻžāϝāĻŧāĨ¤
đĢ Caution:
âĸ ⧝ā§Ļ āĻĻāĻŋāύā§āϰ āĻŦā§āĻļāĻŋ DAPT āĻāĻžāϞāĻžāϞ⧠hemorrhage risk āĻŦā§āĻĄāĻŧā§ āϝāĻžāϝāĻŧ (NNT = 269, NNTH = 132)āĨ¤
đ 3. Alternative Antiplatelet Therapy: Cilostazol & Newer Approaches
đš Cilostazol: A Safer Alternative?
āĻāĻŋāĻā§ āĻā§āώā§āϤā§āϰ⧠Cilostazol (100 mg BID) āĻā§ long-term antiplatelet alternative āĻšāĻŋāϏā§āĻŦā§ āĻŦāĻŋāĻŦā§āĻāύāĻž āĻāϰāĻž āϝā§āϤ⧠āĻĒāĻžāϰā§āĨ¤
đ Clinical Evidence:
âĸ CSPS .com Trial (2010, Japan): Cilostazol aspirin-āĻāϰ āϏāĻŽāĻĒāϰāĻŋāĻŽāĻžāĻŖ stroke prevention āĻĻā§āϝāĻŧ, āϤāĻŦā§ bleeding risk āĻāĻŽāĨ¤
âĸ Asian Population-āĻ Cilostazol-āĻāϰ hemorrhagic risk āĻāĻŽ āĻĨāĻžāĻāĻžāϝāĻŧ āĻāĻāĻŋ preferred choice āĻšāϤ⧠āĻĒāĻžāϰā§āĨ¤
đš Newer Agents Under Investigation
âī¸ Ticagrelor (PLATO Trial) â āĻāĻŋāĻā§ āĻā§āώā§āϤā§āϰ⧠Clopidogrel-āĻāϰ āĻŦāĻŋāĻāϞā§āĻĒ āĻšāϤ⧠āĻĒāĻžāϰā§, āϤāĻŦā§ āĻāĻāύ⧠guideline recommended āύāϝāĻŧāĨ¤
âī¸ Vorapaxar (TRA 2P-TIMI 50 Trial) â Platelet thrombin receptor blocker, āϤāĻŦā§ hemorrhage risk āĻŦā§āĻļāĻŋāĨ¤
âī¸ Rivaroxaban (NAVIGATE ESUS Trial) â Embolic stroke-āĻ promising result, āϤāĻŦā§ TIA āĻŦāĻž non-cardioembolic stroke-āĻ āĻŦā§āϝāĻŦāĻšā§āϤ āĻšāϝāĻŧ āύāĻžāĨ¤

â ī¸ 4. Prevention & Long-Term Stroke Risk Reduction
đš Key Preventive Strategies:
â Blood pressure control (target <130/80 mmHg)
â Diabetes management (HbA1c < 7%)
â Lipid lowering therapy (Statin, LDL < 70 mg/dL)
â Smoking cessation đ
â Weight loss & exercise đââī¸ (at least 150 min/week moderate-intensity exercise)
â Atrial fibrillation āĻĨāĻžāĻāϞ⧠oral anticoagulation (DOACs or Warfarin) āĻĻā§āĻāϝāĻŧāĻž āĻāĻāĻŋāϤāĨ¤
đ SPARCL Trial (2006): Statins (Atorvastatin 80 mg) āĻŦā§āϝāĻŦāĻšāĻžāϰ āĻāϰāϞ⧠stroke recurrence 16% āĻāĻŽā§ āϝāĻžāϝāĻŧāĨ¤
đĸ đŦ Future Research & Emerging Therapies
đ Ticagrelor + Aspirin (THALES Trial, 2020):
âĸ Ticagrelor + Aspirin āĻŦā§āϝāĻŦāĻšāĻžāϰ āĻāϰāϞ⧠minor stroke-āĻāϰ risk 17% āĻāĻŽā§, āϤāĻŦā§ bleeding risk āĻāĻŋāĻā§āĻāĻž āĻŦā§āĻļāĻŋāĨ¤
âĸ Future guidelines-āĻ Ticagrelor-āĻā§ DAPT alternative āĻšāĻŋāϏā§āĻŦā§ āĻŦāĻŋāĻŦā§āĻāύāĻž āĻāϰāĻž āĻšāϤ⧠āĻĒāĻžāϰā§āĨ¤
đ PCSK9 Inhibitors & Stroke Prevention (FOURIER Trial, 2017):
âĸ LDL < 50 mg/dL āĻšāϞ⧠stroke recurrence 27% āĻāĻŽā§āĨ¤
đ¯ Key Takeaways & Practical Approach
â High-risk TIA/Minor Stroke āĻšāϞ⧠āĻĻā§āϰā§āϤ DAPT āĻļā§āϰ⧠āĻāϰāĻž āĻāĻāĻŋāϤ (21 days Clopidogrel + Aspirin, then monotherapy)āĨ¤
â Intracranial stenosis āĻĨāĻžāĻāϞ⧠90 āĻĻāĻŋāύ DAPT āĻāĻžāϞāĻžāύ⧠āϝāĻžāϝāĻŧāĨ¤
â Long-term secondary prevention-āĻ Aspirin, Clopidogrel āĻŦāĻž Cilostazol āĻŦā§āϝāĻŦāĻšāĻžāϰ āĻāϰāĻž āϝā§āϤ⧠āĻĒāĻžāϰā§āĨ¤
â Hypertension, Diabetes, Hyperlipidemia, Smoking cessation â āĻāĻā§āϞ⧠stroke recurrence prevent āĻāϰāϤ⧠essentialāĨ¤
đ Early aggressive antiplatelet therapy, risk factor modification, āĻāĻŦāĻ personalized treatment approach stroke recurrence āĻāĻŽāĻžāϤ⧠āĻ
āϤā§āϝāύā§āϤ āĻā§āϰā§āϤā§āĻŦāĻĒā§āϰā§āĻŖ!
Dr_M_R_Sifat
Share this blog to social media:
Tags:
Suggested post
No post related to the current post. Please click on 'view more' to see more posts